Thrombectomy Penetration Remains Low

And why point-of-care diagnostics may be the fastest way to change it

Mechanical thrombectomy is no longer an emerging therapy. It is one of the clearest advances in acute stroke care over the past decade, supported by strong clinical evidence, stable reimbursement, and broadening guideline support. In clinical terms, the debate has largely been settled. For the right patients, treated quickly enough, thrombectomy changes outcomes. And yet the market remains materially underpenetrated.

That matters because it reveals something important about where the real bottleneck in stroke care now sits. The primary constraint is no longer whether thrombectomy works. It is whether stroke systems can identify the right patients early enough, classify them accurately enough, and move them quickly enough to reach intervention while it can still make a difference.

In other words, thrombectomy has won the evidence battle. It has not yet won the workflow battle.

A large opportunity, still poorly captured

The scale of underpenetration remains striking. Mechanical thrombectomy penetration is ~5% of all acute ischaemic stroke patients in the US. A multinational survey spanning 75 countries found that median global access to mechanical thrombectomy was just 2.8%. More tellingly, 7 countries had 0% access, and 18 countries remained below 1%. Those are not marginal gaps. They are signals of a market that remains structurally constrained at the system level, despite the therapy's clinical maturity.

This is a critical distinction. Underpenetration in thrombectomy is not primarily a problem of weak value proposition, uncertain efficacy, or inadequate procedural economics. It is a problem of pathway leakage. Too many patients fall out of the system before definitive treatment ever becomes possible. Some arrive too late. Some are not recognised early as likely large-vessel occlusions. Some are routed first to hospitals that cannot perform thrombectomy. Others lose time in imaging bottlenecks, transfer delays, or fragmented decision-making between sites. That is why we believe the next phase of value creation in stroke is increasingly shifting upstream.

Where the market is actually being won or lost

The industry often focuses on the procedural endpoint — the thrombectomy device, the intervention itself, and the hospital performing the case. But from a strategic perspective, the real control point often sits earlier in the pathway. If stroke systems can move meaningful diagnostic insight closer to first contact, they can change the numerator, not just optimize the denominator.

Earlier identification of severe stroke, faster differentiation of ischemic versus hemorrhagic presentation, better recognition of likely large-vessel occlusion, and more confident routing to thrombectomy-capable centers can all increase the share of patients who remain eligible by the time intervention is available. The 2026 AHA acute ischemic stroke guidance reinforces this direction through refined EMS triage, broader thrombectomy eligibility, and endorsement of mobile stroke units and related prehospital workflow improvements.

Not just faster care but higher yield

As thrombectomy eligibility expands to broader patient groups, including populations supported by recent large-core stroke data, the dependence on effective front-end assessment only increases. A broader treatable population is only commercially meaningful if the system can actually find those patients and move them in time. Otherwise, expanded indication increases theoretical market size without a proportional increase in realized procedure volume.

That is why we believe better point-of-care diagnostics are not simply adjunctive to thrombectomy adoption. We believe they will be a decisive determinant of real-world penetration.

Seen through that lens, the next phase of value creation in stroke may not come solely from better catheters, aspiration systems, or stent retrievers. It may come from technologies that shift diagnosis and triage earlier in the pathway, where minutes remain to save. The more effective thrombectomy becomes, the more valuable upstream tools become, because every diagnostic minute recovered can translate into more patients treated, better outcomes, and higher utilization of downstream interventional infrastructure.

Commercial activity is beginning to reflect this shift

Recent commercial activity supports this thesis. Medtronic’s March 10, 2026 agreement to acquire Scientia Vascular for USD550 million is instructive not only for the asset itself, but also for how the company framed the transaction. The deal was positioned around combining access and therapeutic capabilities in neurovascular care. The language suggests the market is not thinking about thrombectomy only as a stand-alone device category, but increasingly as a pathway that includes access, speed, procedural simplicity, and workflow execution.

The same pattern is visible in Medtronic’s 2025 partnership with Methinks AI, which aimed to integrate AI-enabled stroke assessment with its treatment portfolio to improve connectivity between stroke centres and regional hospitals. Strategically, that is a meaningful signal. It reflects an understanding that faster assessment, better coordination, and earlier triage are not peripheral to intervention but part of what determines procedural volume in the first place.

Where Wellumio fits

For Wellumio, this is the strategic opening. If thrombectomy remains underpenetrated because stroke systems lose patients before definitive treatment, then a point-of-care imaging or diagnostic platform is doing more than improving workflow efficiency. It is helping expand the treated market itself.

In this paradigm, point-of-care does not compete with thrombectomy. It feeds it. It increases the probability that the right patient is recognised early, escalated appropriately, and delivered into a pathway where intervention can still matter. It helps convert more suspected strokes into actionable stroke decisions, and more actionable decisions into treated patients.

In short, point-of-care diagnostics may become one of the most important enablers of thrombectomy market expansion because they act at the stage where the greatest leakage still occurs. And as the market matures, the companies that help more patients reach thrombectomy in time may prove just as important as the companies that perform the procedure itself.

Download a copy of this Market Insight Article

Thrombectomy Penetration Remains Low (1).pdf

Download PDF • 2.13MB